Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy

TY - JOUR

T1 - Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy

AU - Madsen, Caroline B

AU - Wandall, Hans H

AU - Pedersen, Anders Elm

PY - 2013/12

Y1 - 2013/12

N2 - MUC1 is an important target for antibodies in passive cancer immunotherapy. Antibodies against mucin glycans or mucin peptide backbone alone may give rise to cross reactivity with normal tissues. Therefore, attempts to identify antibodies against cancer-specific MUC1 glycopeptide epitopes havebeen made. We recently demonstrated that a monoclonal antibody against the immunodominant Tn-MUC1 (GalNAc-α-MUC1) antigen induced ADCC in breast cancer cell lines, suggesting the feasibility of targeting combined glycopeptide epitopes in future passive cancer immunotherapy.

AB - MUC1 is an important target for antibodies in passive cancer immunotherapy. Antibodies against mucin glycans or mucin peptide backbone alone may give rise to cross reactivity with normal tissues. Therefore, attempts to identify antibodies against cancer-specific MUC1 glycopeptide epitopes havebeen made. We recently demonstrated that a monoclonal antibody against the immunodominant Tn-MUC1 (GalNAc-α-MUC1) antigen induced ADCC in breast cancer cell lines, suggesting the feasibility of targeting combined glycopeptide epitopes in future passive cancer immunotherapy.

U2 - 10.3109/08923973.2013.837060

DO - 10.3109/08923973.2013.837060

M3 - Journal article

C2 - 24063621

SN - 0892-3973

VL - 35

SP - 649

EP - 652

JO - Immunopharmacology and Immunotoxicology

JF - Immunopharmacology and Immunotoxicology

IS - 6

ER -